Genome sequencing: The Future of Preventive Healthcare

Genome sequencing — the ability to read the complete DNA sequence of an individual — is rapidly moving from research laboratories into clinical practice and consumer health. As costs continue to fall and our ability to interpret genomic data improves, genome sequencing is poised to become the foundation of preventive healthcare — enabling truly personalized medicine at a scale previously unimaginable.

From Research Tool to Clinical Reality

The first human genome was sequenced in 2003 at a cost of approximately $3 billion and took 13 years. Today, a whole genome can be sequenced in days for under $500 — and costs continue to fall. This dramatic reduction in cost and time has transformed genome sequencing from a research curiosity into a practical clinical tool.

Whole genome sequencing (WGS) sequences all 3 billion base pairs of the human genome, providing the most comprehensive genetic information available. Whole exome sequencing (WES) sequences only the protein-coding regions (approximately 1–2% of the genome), which contain approximately 85% of known disease-causing mutations — at lower cost and with more established clinical interpretation frameworks.

How Genome Sequencing Is Transforming Preventive Healthcare

Comprehensive Disease Risk Assessment

Genome sequencing identifies both rare high-impact variants (like BRCA1/2 mutations) and common variants that collectively influence risk for common diseases. Polygenic risk scores — which aggregate the effects of thousands of common variants — can identify individuals at high genetic risk for cardiovascular disease, type 2 diabetes, breast cancer, and other common conditions — enabling targeted preventive interventions decades before disease develops.

Pharmacogenomics

A single genome sequence contains all the pharmacogenomic information needed to optimize medication selection and dosing across a lifetime. Rather than testing individual genes for specific medications, genome sequencing provides a comprehensive pharmacogenomic profile that can be queried whenever a new medication is prescribed.

Carrier Screening

Genome sequencing identifies carrier status for hundreds of recessive genetic conditions simultaneously — enabling comprehensive preconception and prenatal counselling without the need for multiple targeted tests.

Rare Disease Diagnosis

For patients with unexplained symptoms, genome sequencing has a higher diagnostic yield than exome sequencing — identifying causes in non-coding regions that exome sequencing misses. As our understanding of non-coding variants improves, the diagnostic yield of genome sequencing will continue to increase.

The Indian Opportunity

India's extraordinary genetic diversity — shaped by thousands of years of migration, endogamy, and cultural exchange — makes genome sequencing particularly valuable and particularly challenging. Building India-specific genomic reference databases is critical for ensuring that genetic insights are accurate and relevant for Indian patients. MapmyGenome is at the forefront of this effort, building the largest Indian genomic database to improve the accuracy of genetic risk assessment for Indian populations.

FAQs

What is the difference between genome sequencing and a genetic health test like Genomepatri?

Consumer genetic health tests like Genomepatri analyze specific genetic variants (SNPs) associated with health conditions and traits — providing actionable health insights at an accessible price point. Whole genome sequencing provides a complete DNA sequence, enabling more comprehensive analysis including rare variants and non-coding regions. Both have important roles in preventive healthcare.

Is genome sequencing available in India?

Yes. MapmyGenome offers whole exome sequencing and targeted gene panels in India, processed in our NABL-certified laboratory. Whole genome sequencing is also available for clinical indications.